Ortho-K vs Atropine Drops for Myopia Control
These are the two best-studied ways to slow myopia progression in children, and they work by completely different mechanisms. Ortho-K is optical: it reshapes the cornea so peripheral light focuses differently, and it corrects daytime vision as a bonus. Low-dose atropine is pharmacological: a nightly drop that slows eye growth through a receptor pathway that is still not fully understood, and it does nothing for the child's vision. Many families end up choosing between them. Some use both.
On this page
How Each One Works
What is the difference between Ortho-K and atropine for myopia control?
Ortho-K is an optical treatment. Overnight lenses reshape the cornea so peripheral light focuses in front of the retina, a signal associated with slower eye growth, while central vision is corrected at the same time. Atropine is a diluted eye drop used nightly that slows axial elongation through a pharmacological pathway but provides no vision correction.
The optical story is reasonably well established. A reshaped cornea creates peripheral myopic defocus, and eyes exposed to that signal elongate more slowly in both animal models and human trials. The child sees clearly during the day with nothing worn, which is why Ortho-K does two jobs at once.
Atropine is more of an open question mechanistically. It is a muscarinic antagonist, originally used at full strength to dilate the pupil and relax accommodation, and the myopia control effect appears to work through receptors in the retina or sclera rather than through accommodation as was once assumed. Concentrations used for myopia control are heavily diluted, commonly in the range of 0.01 to 0.05 percent, and are compounded rather than sold as a standard commercial product in most cases.
Side by Side
| Factor | Ortho-K | Low-dose atropine |
|---|---|---|
| Corrects daytime vision | Yes, with nothing worn during the day | No. Glasses or contacts still required. |
| Daily burden | Insertion, removal, cleaning, roughly ten minutes | One drop at bedtime, under a minute |
| Evidence base | Multiple controlled trials on axial elongation | Multiple controlled trials, including large multi-year studies |
| Common side effects | Lens awareness, transient dryness, halos early on | Light sensitivity and near blur, dose dependent |
| Main risk | Microbial keratitis, tied to hygiene | Very low at diluted concentrations; systemic effects are rare |
| Handling skill required | Yes. Training and verification needed. | Minimal. Most parents manage it immediately. |
| Works for high astigmatism | Limited. Depends on corneal shape. | Unaffected by astigmatism |
| Rebound on stopping | Vision returns to baseline; no progression rebound reported | Rebound acceleration reported, especially at higher doses |
| Cost shape | Program starting at $1,800, then ongoing care | Recurring compounded prescription cost |
Effect sizes for the two treatments overlap in the published literature, and head-to-head comparisons are limited enough that claiming a clear winner would overstate the evidence. See Clinical Evidence for how we read the studies.
Which One Fits Your Child
The choice usually comes down to three practical questions rather than to which treatment is theoretically superior.
- Does the child want to be out of glasses? If yes, Ortho-K delivers that and atropine does not. For an athletic ten year old this is often decisive.
- Will the household sustain a lens routine? If handling, hygiene, and case management are unrealistic, atropine asks far less and a treatment that gets used beats a better treatment that does not.
- Is the cornea suitable? High or irregular astigmatism and certain corneal conditions limit what Ortho-K can achieve. Atropine is indifferent to corneal shape.
Combination Therapy
Ortho-K and low-dose atropine can be used together, and there is a growing body of evidence suggesting the combination slows axial elongation more than either treatment alone in children who are progressing rapidly. The two mechanisms are independent, which is the reason to expect an additive effect.
In practice, combination therapy is not where we start. It is what we consider when a child on one treatment continues to show axial elongation beyond what we expect for their age, which is exactly the kind of question that requires measurement rather than impression. This is why axial length monitoring is built into the program from the first visit: without a baseline and a trend line, there is no defensible basis for escalating treatment.
- Typical trigger. Continued axial elongation on a six-month remeasurement despite good compliance with a single treatment.
- How it is run. Lenses continue on their normal schedule, with the drop instilled before lens insertion at bedtime unless directed otherwise.
- What we watch. Axial length trend, corneal health, light sensitivity, and whether near work at school has become uncomfortable.
- When we stop. Atropine is normally tapered rather than stopped abruptly, because rebound acceleration has been reported after sudden discontinuation.
What Both Approaches Require
- A baseline axial length measurement. Without it, you cannot tell whether either treatment is working. Prescription alone is too noisy.
- Scheduled remeasurement. We remeasure on a defined interval and chart the result against expected age-matched growth.
- Honest compliance reporting. A treatment used four nights a week is a different treatment. Tell us the truth and we can adjust.
- Time outdoors and sensible near-work breaks. These are the floor for every child regardless of treatment.
- A willingness to change course. If the numbers say a treatment is not doing its job, the right response is to change something.
Read Axial Length Monitoring for how the measurement works, and the Parent Guide to Ortho-K for the practical side of running a program at home.
Frequently Asked Questions
Which is more effective at slowing progression?
The published effect sizes overlap substantially and direct head-to-head trials are limited, so an honest answer is that neither has been shown to be clearly superior for all children.
The practical difference is that Ortho-K also corrects vision, while atropine requires the child to keep wearing glasses.
What are the side effects of low-dose atropine?
Light sensitivity and blur at near are the usual complaints, and both are dose dependent. At the lowest concentrations many children notice nothing at all.
Higher concentrations control progression more strongly but produce more symptoms and a larger rebound when stopped, which is the trade-off behind the move toward lower doses.
Does Better Sight Overnight prescribe atropine?
Myopia management here is built around Ortho-K and axial length monitoring. Where atropine is appropriate, including as combination therapy, we discuss it as part of the overall plan and coordinate with the prescribing clinician.
Bring it up at the consultation. The right plan is the one that fits the child, not the one that fits our equipment.
Is it safe to use drops and Ortho-K lenses together?
It is done routinely in myopia clinics, with the drop typically instilled before lens insertion at bedtime. The two do not interfere mechanically.
It is still a prescribing decision that depends on the individual child, and it should be supervised with scheduled axial length remeasurement.
What happens when a child stops atropine?
Rebound acceleration of myopia progression has been reported after abrupt discontinuation, more prominently at higher concentrations. Tapering is the usual approach.
Ortho-K does not show that pattern. Stopping returns the cornea to its original shape and vision to baseline, without an observed surge in progression.
Is one better for a very young child?
For a child too young for lens handling, a bedtime drop is far easier to sustain and is frequently the more realistic starting point.
As the child matures and becomes capable of handling lenses, switching to or adding Ortho-K becomes worth revisiting.
Keep reading
Last updated . Clinically reviewed by Dr. Mark Page.